625435-02-1 Usage
Uses
Used in Pharmaceutical Industry:
Benzenemethanamine, N-cyclopropyl-2-fluoro(9CI) is used as a research chemical for the development of new medications, given its stimulant and psychoactive properties. It aids in understanding the mechanisms of action and potential therapeutic applications of amphetamine-like compounds.
Used in Scientific Research:
In the field of neuroscience and psychopharmacology, Benzenemethanamine, N-cyclopropyl-2-fluoro(9CI) serves as a research tool to study the effects of amphetamines on the central nervous system. This helps in advancing knowledge about the neurobiological underpinnings of stimulant action and addiction.
Check Digit Verification of cas no
The CAS Registry Mumber 625435-02-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,5,4,3 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 625435-02:
(8*6)+(7*2)+(6*5)+(5*4)+(4*3)+(3*5)+(2*0)+(1*2)=141
141 % 10 = 1
So 625435-02-1 is a valid CAS Registry Number.
625435-02-1Relevant articles and documents
NOVEL COMPOUNDS AS INHIBITORS OF RENIN
-
Page/Page column 10, (2012/05/20)
The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to
NOVEL COMPOUNDS AS INHIBITORS OF RENIN
-
Page/Page column 20, (2010/11/05)
The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to
NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES
-
Page 24, (2010/02/09)
The invention relates to novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including proc